TP53 and cancer: We previously conducted a series of cancer patient-derived xenograft (PDX) studies, during which we observed that ATO could effectively rescue p53-R282W (based on the observed protein-level upregulation of p53 targets) and inhibited human colon and pancreas PDX models (CR2258 and PA1233 models).34